BR0009765A - Esteres de l-carnitina ou alcanoil l-carnitinas úteis como lipìdios catiÈnicos para a distribuição intracelular de compostos farmacologicamente ativos - Google Patents

Esteres de l-carnitina ou alcanoil l-carnitinas úteis como lipìdios catiÈnicos para a distribuição intracelular de compostos farmacologicamente ativos

Info

Publication number
BR0009765A
BR0009765A BR0009765-9A BR0009765A BR0009765A BR 0009765 A BR0009765 A BR 0009765A BR 0009765 A BR0009765 A BR 0009765A BR 0009765 A BR0009765 A BR 0009765A
Authority
BR
Brazil
Prior art keywords
carnitine
alkanoyl
active compounds
pharmacologically active
carnitines
Prior art date
Application number
BR0009765-9A
Other languages
English (en)
Other versions
BR0009765B1 (pt
Inventor
Claudio Pisano
Maria Ornella Tinti
Mose Santaniello
Luciana Critelli
Giovanni Salvatori
Original Assignee
Sigma Tau Ind Farmaceuthiche R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuthiche R filed Critical Sigma Tau Ind Farmaceuthiche R
Priority to BRPI0017460A priority Critical patent/BRPI0017460B1/pt
Publication of BR0009765A publication Critical patent/BR0009765A/pt
Publication of BR0009765B1 publication Critical patent/BR0009765B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Patente de Invenção: "éSTERES DE L-CARNITINA OU ALCANOIL L-CARNITINAS úTEIS COMO LIPìDIOS CATIÈNICOS PARA A DISTRIBUIçãO INTRACELULAR DE COMPOSTOS FARMACOLOGICAMENTE ATIVOS". ésteres de L-carnitina e alcanoil L-carnitinas são descritos, os quais podem ser usados como lipídios catiónicos para a distribuição intracelular de compostos farmacologicamente ativos. Novos ésteres de L-carnitina e alcanoil L-carnitina da fórmula (1) também são divulgados, em que os grupos R são conforme definidos na descrição.
BRPI0009765-9B1A 1999-04-13 2000-04-11 Compostos de ésteres de l-carnitina ou alcanoil l-carnitinase, uso dos mesmos, lipossomas contendo os referidos compostos e composições farmacêuticas e cosméticas contendo os ditos lipossomas. BR0009765B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI0017460A BRPI0017460B1 (pt) 1999-04-13 2000-04-11 uso de lipossomos consistindo de ésteres de l-carnitina

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999RM000220A IT1306129B1 (it) 1999-04-13 1999-04-13 Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
PCT/IT2000/000137 WO2000061543A2 (en) 1999-04-13 2000-04-11 Esters of l-carnitine or alkanoyl l-carnitines

Publications (2)

Publication Number Publication Date
BR0009765A true BR0009765A (pt) 2002-01-02
BR0009765B1 BR0009765B1 (pt) 2013-11-05

Family

ID=11406659

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0009765-9B1A BR0009765B1 (pt) 1999-04-13 2000-04-11 Compostos de ésteres de l-carnitina ou alcanoil l-carnitinase, uso dos mesmos, lipossomas contendo os referidos compostos e composições farmacêuticas e cosméticas contendo os ditos lipossomas.
BRPI0017460A BRPI0017460B1 (pt) 1999-04-13 2000-04-11 uso de lipossomos consistindo de ésteres de l-carnitina

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0017460A BRPI0017460B1 (pt) 1999-04-13 2000-04-11 uso de lipossomos consistindo de ésteres de l-carnitina

Country Status (34)

Country Link
US (4) US6797281B1 (pt)
EP (3) EP1426044B1 (pt)
JP (2) JP4703855B2 (pt)
KR (2) KR100798499B1 (pt)
CN (2) CN100402017C (pt)
AT (2) ATE317257T1 (pt)
AU (2) AU776301B2 (pt)
BG (3) BG65501B1 (pt)
BR (2) BR0009765B1 (pt)
CA (2) CA2370143C (pt)
CZ (1) CZ302628B6 (pt)
DE (2) DE60025961T2 (pt)
DK (2) DK1183228T3 (pt)
EA (2) EA004459B1 (pt)
EE (2) EE05514B1 (pt)
ES (2) ES2258688T3 (pt)
HK (2) HK1045145B (pt)
HR (1) HRP20010740B1 (pt)
HU (1) HU229366B1 (pt)
IL (4) IL145765A0 (pt)
IS (2) IS2476B (pt)
IT (1) IT1306129B1 (pt)
ME (2) ME00113B (pt)
MX (1) MXPA01010359A (pt)
NO (2) NO327742B1 (pt)
NZ (2) NZ515270A (pt)
PL (2) PL211710B1 (pt)
PT (2) PT1183228E (pt)
RS (3) RS50911B (pt)
SI (2) SI1183228T1 (pt)
SK (2) SK287253B6 (pt)
TR (2) TR200202358T2 (pt)
WO (1) WO2000061543A2 (pt)
ZA (1) ZA200109291B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051454A1 (en) * 2000-01-13 2001-07-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE10113446A1 (de) † 2001-03-19 2002-09-26 Schwarzkopf Gmbh Hans Haarbehandlungsmittel mit Betainen
DE60329497D1 (de) 2002-06-26 2009-11-12 Medigene Ag Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend
PT2286795T (pt) * 2002-06-26 2017-01-27 Syncore Biotechnology Co Ltd Processo de produção de uma preparação lipossomal catiónica que compreende um composto lipófilo
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
EP1868571A4 (en) * 2005-03-02 2011-10-26 Univ Northeastern MITOCHONDRIOTROPIC PHOSPHOLIPIDE VESICLES
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
AU2006277960A1 (en) * 2005-08-10 2007-02-15 Novartis Ag Formulations for 7-(T-butoxy)iminomethyl camptothecin
AR055602A1 (es) * 2005-08-10 2007-08-29 Novartis Ag Una composicion farmaceutica de microparticulas de 7-terbutoxi-imino-metil-camptotecina
WO2008024389A2 (en) * 2006-08-23 2008-02-28 Biodelivery Sciences International, Inc. Amphiphilic nucleotide cochleate compositions and methods of using the same
US20100166843A1 (en) * 2007-02-01 2010-07-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
WO2008101173A2 (en) * 2007-02-16 2008-08-21 Cornell University Biodegradable compositions and materials
WO2008144881A1 (en) 2007-05-28 2008-12-04 Genesis Group Inc. Biodegradable elastomers prepared by the condensation of an organic di-, tri- or tetra-carboxylic acid and an organic diol
EP2532643A1 (en) 2007-06-08 2012-12-12 MannKind Corporation IRE-1A Inhibitors
US8173784B2 (en) 2008-03-13 2012-05-08 Perkinelmer Health Sciences, Inc. Enzymatic substrates for multiple detection systems
EP2532649B1 (en) * 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
AU2014233084B2 (en) 2013-03-15 2019-09-19 Perkinelmer Health Sciences, Inc. Compounds and methods relating to testing for lysosomal storage disorders
EP3423044A4 (en) 2016-03-02 2019-11-20 The Board of Regents of The University of Texas System STING-ACTIVATING NANO VACCINE FOR IMMUNOTHERAPY
US11103588B2 (en) 2017-06-06 2021-08-31 Wayne State University Methods and compositions relating to carnitine-derived materials
CN115177608B (zh) * 2022-07-26 2023-12-05 南方医科大学南方医院 长链酰基肉碱类化合物在制备预防和/或治疗肝癌的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008288A (en) * 1986-01-06 1991-04-16 Alfred Stracher Carnitine directed pharmaceutical agents
US4866040A (en) * 1986-01-06 1989-09-12 Alfred Stracher Aminocarnitine directed pharmaceutical agents
IT1230142B (it) * 1989-05-03 1991-10-14 Fidia Spa Derivati della carnitina, processo per la loro preparazione e impiego in terapia umana
CA2085354C (en) * 1990-06-15 2002-08-27 Claude Piantadosi Ether lipid-nucleoside covalent conjugates
IT1248321B (it) * 1991-05-15 1995-01-05 Sigma Tau Ind Farmaceuti Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie
IT1258370B (it) * 1992-03-02 1996-02-26 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil l-carnitine dotati di attivita' miorilassante selettiva sull'apparato gastro-intestinale e composizioni farmaceutiche che li contengono.
US5972600A (en) * 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
IT1263013B (it) * 1992-10-20 1996-07-23 Avantgarde Spa Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
IT1261984B (it) * 1993-06-22 1996-06-11 Avantgarde Spa Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
JPH08512056A (ja) * 1993-06-30 1996-12-17 ジェネンテク・インコーポレイテッド リポソームの製造法
IT1273987B (it) * 1994-09-29 1997-07-14 Sigma Tau Ind Farmaceuti Uso di esteri ftalidilidenici della carnitina e di alcanoil carnitine per il trattamento dello shock endotossico
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
JP2001516329A (ja) * 1995-06-07 2001-09-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ポリヌクレオチド複合体の安定化
IT1283955B1 (it) * 1996-03-20 1998-05-07 Sigma Tau Ind Farmaceuti Bis alcanoil esteri della carnitina ad attivita' antibatterica, antimicotica ed antiprotozoaria.
US6294378B1 (en) * 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
IT1299172B1 (it) * 1998-05-06 2000-02-29 Sigma Tau Ind Farmaceuti Esteri perfluorurati di alcanoil l-carnitine utilizzabili quali lipidi cationici per l'immissione intracellulare di composti

Also Published As

Publication number Publication date
RS50911B (sr) 2010-08-31
NO20014985L (no) 2001-10-12
EE201100028A (et) 2011-08-15
HK1045145B (zh) 2006-01-27
IT1306129B1 (it) 2001-05-30
EA200300745A1 (ru) 2003-12-25
WO2000061543A3 (en) 2001-01-11
BG65501B1 (bg) 2008-10-31
KR20060113799A (ko) 2006-11-02
SK14312001A3 (sk) 2002-02-05
ATE286873T1 (de) 2005-01-15
BG109876A (en) 2008-02-29
BRPI0017460B1 (pt) 2016-04-19
IS2539B (is) 2009-09-15
SI1183228T1 (en) 2005-04-30
ITRM990220A1 (it) 2000-10-13
HUP0201446A3 (en) 2002-11-28
EP1426044B1 (en) 2006-02-08
BG65312B1 (bg) 2008-01-31
EP1426044A1 (en) 2004-06-09
BG105971A (en) 2002-08-30
US20050079209A1 (en) 2005-04-14
EA200101076A1 (ru) 2002-04-25
ME00113B (me) 2010-10-10
IL145765A (en) 2007-07-04
AU2004224958A1 (en) 2004-11-25
EA006021B1 (ru) 2005-08-25
EP1183228B1 (en) 2005-01-12
US7629003B2 (en) 2009-12-08
IL145765A0 (en) 2002-07-25
TR200102941T2 (tr) 2002-05-21
KR100798499B1 (ko) 2008-01-28
PT1426044E (pt) 2006-06-30
AU2004224958B2 (en) 2007-11-22
KR100684378B1 (ko) 2007-02-20
EP1435232A1 (en) 2004-07-07
DK1183228T3 (da) 2005-05-17
DE60017388T2 (de) 2006-03-30
ZA200109291B (en) 2002-08-16
IL175366A0 (en) 2006-09-05
CA2370143C (en) 2011-06-21
DK1426044T3 (da) 2006-06-12
NO20014985D0 (no) 2001-10-12
HUP0201446A2 (en) 2002-08-28
EE05719B1 (et) 2014-08-15
DE60017388D1 (de) 2005-02-17
US7585519B2 (en) 2009-09-08
RS20090448A (en) 2010-06-30
HRP20010740B1 (en) 2005-08-31
US20070190128A1 (en) 2007-08-16
CN1823731A (zh) 2006-08-30
MXPA01010359A (es) 2002-05-06
US20040186175A1 (en) 2004-09-23
HRP20010740A2 (en) 2002-10-31
JP2002541238A (ja) 2002-12-03
NO327742B1 (no) 2009-09-14
EE05514B1 (et) 2012-02-15
SI1426044T1 (sl) 2006-04-30
NZ515270A (en) 2004-02-27
PL351112A1 (en) 2003-03-24
KR20010113794A (ko) 2001-12-28
JP4703855B2 (ja) 2011-06-15
PT1183228E (pt) 2005-04-29
DE60025961T2 (de) 2006-08-17
NO20085413L (no) 2001-10-12
PL204418B1 (pl) 2010-01-29
AU4312300A (en) 2000-11-14
CA2370143A1 (en) 2000-10-19
ATE317257T1 (de) 2006-02-15
RS52682B (en) 2013-08-30
WO2000061543A2 (en) 2000-10-19
CN1359370A (zh) 2002-07-17
NO336949B1 (no) 2015-11-30
CN1263730C (zh) 2006-07-12
EE200100518A (et) 2002-12-16
CZ302628B6 (cs) 2011-08-10
IS2476B (is) 2008-12-15
CN100402017C (zh) 2008-07-16
IS6095A (is) 2001-09-28
CA2650202A1 (en) 2000-10-19
PL211710B1 (pl) 2012-06-29
ES2234591T3 (es) 2005-07-01
DE60025961D1 (de) 2006-04-20
JP5420507B2 (ja) 2014-02-19
EA004459B1 (ru) 2004-04-29
HK1045145A1 (en) 2002-11-15
IS8719A (is) 2008-03-07
IL185486A0 (en) 2008-01-06
EP1183228A2 (en) 2002-03-06
US6797281B1 (en) 2004-09-28
BR0009765B1 (pt) 2013-11-05
AU776301B2 (en) 2004-09-02
NZ528874A (en) 2005-09-30
HK1092732A1 (en) 2007-02-16
SK287253B6 (sk) 2010-04-07
YU70201A (sh) 2004-07-15
TR200202358T2 (tr) 2002-12-23
CZ20013617A3 (cs) 2002-02-13
JP2011042657A (ja) 2011-03-03
MEP24008A (en) 2010-06-10
CA2650202C (en) 2012-12-11
ES2258688T3 (es) 2006-09-01
HU229366B1 (en) 2013-11-28
IL175366A (en) 2010-12-30
SK288246B6 (sk) 2015-03-03

Similar Documents

Publication Publication Date Title
BR0009765A (pt) Esteres de l-carnitina ou alcanoil l-carnitinas úteis como lipìdios catiÈnicos para a distribuição intracelular de compostos farmacologicamente ativos
BR0208373A (pt) Inibidores da tirosina cinase
BR0007781A (pt) Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf
BR0210028A (pt) Agentes antibacterianos
BG106681A (en) Solutions containing epinastine
BR9608488A (pt) Uso de derivados da vitamina d4 no tratamento de câncer
BRPI0108990B8 (pt) processo para preparação de derivados de pirimidona com atividade antifungos
BR9911250A (pt) Processo para preparação de compostos
BR0208504A (pt) Composição farmacêutica estável de pravastatina
ATE272047T1 (de) Perfluorierte ester von alkanoyl l-carnitin zur herstellung von kationischen lipiden zur intrazellulären verabreichung pharmakologisch aktiver verbindungen
BR9714135A (pt) Compostos de tetraidropiridina substituìda, processo para preparação dos mesmos e composições farmacêuticas que os contêm.

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: C07C 229/22 (2008.01), A61K 9/127 (2008.01)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/11/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)